BIOLASE Technology, Inc. (NASDAQ: BLTI), the World’s leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE a new patent covering the use of its laser technologies for treating va…
Author: OphthalmologyWeb
NICE Consults On A New Drug To Treat Diabetic Macular Oedema
In draft guidance issued yesterday, NICE has not recommended ranibizumab (Lucentis, Novartis) for treating diabetic macular oedema (DMO).
Clustering Gene Expression Changes Reveals Pathways Toward Glaucoma Prevention
Glaucoma is the second-most common cause of blindness in the US, and occurs due to loss of retinal ganglion cells and degeneration of the optic nerve. Although it is known that high levels of pressure within the eye predispose individuals to the develo…
Changes In IOP After Cataract Removal Reported For Observation Group Of The OHTS
Cataract surgery lowers IOP by 18% in patients with untreated ocular hypertension, a surgeon reported, giving results derived from the Ocular Hypertension Treatment Study.
Changes In IOP After Cataract Removal Reported For Observation Group Of The OHTS
Cataract surgery lowers IOP by 18% in patients with untreated ocular hypertension, a surgeon reported, giving results derived from the Ocular Hypertension Treatment Study.
ISTA Pharmaceuticals Files Citizen Petition (CP) With U.S. Food And Drug Administration
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), announced it filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) on March 1, 2011. The CP requests the FDA refrain from granting tentative or final approval of any abbreviated new dr…
ISTA Pharmaceuticals Files Citizen Petition (CP) With U.S. Food And Drug Administration
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), announced it filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) on March 1, 2011. The CP requests the FDA refrain from granting tentative or final approval of any abbreviated new dr…
Drop In Temperature May Explain The Increase In Dry Eye Suffering
Springtime may be just what the doctor orders for individuals suffering from dry eye condition, a disorder resulting from insufficient tear production or altered tear film composition. According to a study published in Investigative Ophthalmology & Vis…
Low Incidence Of Retinal Detachment Reported For Patients Receiving Anti-VEGF Injections
The incidence of rhegmatogenous retinal detachment was low in patients who received intravitreal anti-VEGF injections for retinal disease, a study found.
Low Incidence Of Retinal Detachment Reported For Patients Receiving Anti-VEGF Injections
The incidence of rhegmatogenous retinal detachment was low in patients who received intravitreal anti-VEGF injections for retinal disease, a study found.
Drop In Temperature May Explain The Increase In Dry Eye Suffering
Springtime may be just what the doctor orders for individuals suffering from dry eye condition, a disorder resulting from insufficient tear production or altered tear film composition. According to a study published in Investigative Ophthalmology & Vis…
Computer Vision Syndrome: Fact Or Fiction?
Staring into the enticing glow of your computer hour after hour may well have its benefits, but a downside to all that screen time can include dry, tired eyes, blurred vision, fatigue and headaches.
Webinar: Achieving Superior Treatment Accuracy with Navigated Photocoagulation
Featured Article
Interocular Differences In RNFL Thickness May Indicate Early Glaucoma Damage
Normal eyes with interocular differences in retinal nerve fiber layer thickness greater than 9 µm may have early glaucoma damage, according to a study.
Computer Vision Syndrome: Fact Or Fiction?
Staring into the enticing glow of your computer hour after hour may well have its benefits, but a downside to all that screen time can include dry, tired eyes, blurred vision, fatigue and headaches.
Interocular Differences In RNFL Thickness May Indicate Early Glaucoma Damage
Normal eyes with interocular differences in retinal nerve fiber layer thickness greater than 9 µm may have early glaucoma damage, according to a study.
Officials Proclaim Efforts Of New York Eye And Ear Infirmary And Colleagues To Combat Leading Cause Of Blindness
Joining an international effort to raise awareness about the threat of glaucoma, Mayor Michael R. Bloomberg has officially proclaimed March 6-12, 2011 as World Glaucoma Week in New York City. The week is observed around the globe by awareness and educa…
Officials Proclaim Efforts Of New York Eye And Ear Infirmary And Colleagues To Combat Leading Cause Of Blindness
Joining an international effort to raise awareness about the threat of glaucoma, Mayor Michael R. Bloomberg has officially proclaimed March 6-12, 2011 as World Glaucoma Week in New York City. The week is observed around the globe by awareness and educa…
Paloma Pharmaceuticals Update On Ocular Clinical And Oncology Programs
Paloma Pharmaceuticals, Inc. announced today updates on its age-related macular degeneration Phase I trials and oncology program. Palomid 529 (P529), Paloma Pharmaceuticals first-in-class allosteric dual TORC1/TORC2 dissociative inhibitor targeting the…
Paloma Pharmaceuticals Update On Ocular Clinical And Oncology Programs
Paloma Pharmaceuticals, Inc. announced today updates on its age-related macular degeneration Phase I trials and oncology program. Palomid 529 (P529), Paloma Pharmaceuticals first-in-class allosteric dual TORC1/TORC2 dissociative inhibitor targeting the…